The Endpoints Slack interview: How Beam CEO John Evans thinks about the science and business of genetic editing
Even though there were groundbreaking approvals for genetic medicines in sickle cell disease last year, John Evans believes that his start-up can continue to make advancements in the field. Beam Therapeutics began
